Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Multicenter study of over 1000 females with breast cancer, Read More

2026-04-06T09:27:36-04:00March 31st, 2026|Press Releases|
Go to Top